LBA58 Pathological response to neoadjuvant tislelizumab (TIS) plus platinum-doublet (PtDb) chemotherapy (CT) in resectable stage II-IIIA NSCLC patients (pts) in the phase III (Ph3) RATIONALE-315 trial
Dongsheng Yue, Wenxin Wang, Huai Liu, Qing Chen, Chang Chen, Jian Zhang, Fan Bai, C. Wang
Topics & Concepts
MedicineChemotherapyOncologyStage (stratigraphy)Internal medicinePathologicalNeoadjuvant therapyCancerBiologyBreast cancerPaleontologyCancer Immunotherapy and BiomarkersEsophageal Cancer Research and TreatmentRadiopharmaceutical Chemistry and Applications